The effects of Montmorency tart cherry supplementation on cardio-metabolic markers in Metabolic Syndrome participants: a pilot study

Metabolic Syndrome (MetS) encompasses various cardio-metabolic variables and is often a precursor to cardiovascular disease, hypertension, diabetes and obesity (O’Neill et al., 2016). Montmorency tart cherry (MTC) juice consumption showed a significant and clinically relevant reduction in blood pressure within pre-hypertensive, humans (Keane et al., 2016). Genetic research in rodents (Seymour et al., 2008; 2009) suggests MTC positively modulates transcription factors involved in major fat metabolism pathways. Currently, no research has investigated the effects of MTC consumption on cardio-metabolic markers in MetS participants. The aim is to undertake pilot work to determine power analysis data for large-scale clinical trials.